HLB, 117,654 Shares Net Bought by Individuals in Last 5 Days... Stock Price at 111,700 Won (-7.15%)

HLB is trading at 111,700 KRW as of 2:30 PM on the 22nd, down 7.15% from the previous day. The trading volume is 1,388,996 shares, which is 33.88% of the previous day's volume. HLB is known as a manufacturer of lifeboats and fiberglass pipes, as well as a construction company.

On September 18, researcher Oh Byung-yong from Hanyang Securities stated, "At the ESMO conference held on 9/19, as many as 20 studies related to Lenvatinib will be presented. Since the company holds all rights to Lenvatinib except for the Chinese license, it is safe to say that all 20 study results are from the company. The combination therapy of Lenvatinib and Camrelizumab for liver cancer shows very outstanding results. Patient recruitment for the global Phase 3 trial of Lenvatinib + Camrelizumab has surpassed 50%. If the global Phase 3 trial again achieves an ORR of over 40%, the potential for a blockbuster is truly open." He set the target price for HLB at 144,500 KRW.

Over the past five days, individual investors have net purchased 117,654 shares of HLB, while foreigners and institutions have net sold 87,639 shares and 41,865 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.